Evidence map›Paper›PMID 33420354›Full record

ArticleCellular & molecular immunology2021

Potentiation of NETs release is novel characteristic of TREM-1 activation and the pharmacological inhibition of TREM-1 could prevent from the deleterious consequences of NETs release in sepsis.

Amir Boufenzer, Kevin Carrasco, Lucie Jolly, Benjamin Brustolin, Elisa Di-Pillo, Marc Derive, Sébastien Gibot

Open access · hybridAbstract read
In one paragraph

Article in Cellular & molecular immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 88 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Immune dysfunction in Alzheimer disease.Nature reviews. Neuroscience · 2026
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. The role of neutrophils in vasospasm and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: Is it time for a SAH clinical trial targeting neutrophils?Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2025
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution.

Amir BoufenzerINOTREM, Vandœuvre-lès-Nancy, Nancy, France. ab@inotrem.com.
Kevin CarrascoINOTREM, Vandœuvre-lès-Nancy, Nancy, France.
Lucie JollyINOTREM, Vandœuvre-lès-Nancy, Nancy, France.
Benjamin BrustolinUMR-S 1116, Défaillance Cardiovasculaire Aigue et Chronique, Vandœuvre-lès-Nancy, Nancy, France.
Elisa Di-PilloUMR-S 1116, Défaillance Cardiovasculaire Aigue et Chronique, Vandœuvre-lès-Nancy, Nancy, France.
Marc DeriveINOTREM, Vandœuvre-lès-Nancy, Nancy, France.
Sébastien GibotUMR-S 1116, Défaillance Cardiovasculaire Aigue et Chronique, Vandœuvre-lès-Nancy, Nancy, France.
Défaillance Cardiovasculaire Aiguë et Chronique

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During sepsis, neutrophil activation induces endothelial cell (EC) dysfunction partly through neutrophil extracellular trap (NET) release. The triggering receptor expressed on myeloid cell-1 (TREM-1) is an orphan immune receptor that amplifies the inflammatory response mediated by Toll-like receptor-4 (TLR4) engagement. Although the key role of TLR4 signaling in NETosis is known, the role of TREM-1 in this process has not yet been investigated. Here, we report that TREM-1 potentiates NET release by human and murine neutrophils and is a component of the NET structure. In contrast, pharmacologic inhibition or genetic ablation of TREM-1 decreased NETosis in vitro and during experimental septic shock in vivo. Moreover, isolated NETs were able to activate ECs and impair vascular reactivity, and these deleterious effects were dampened by TREM-1 inhibition. TREM-1 may, therefore, constitute a new therapeutic target to prevent NETosis and associated endothelial dysfunction.

Indexed as

AdolescentAdultAgedAnimalsEndothelium, VascularExtracellular TrapsHealthy VolunteersHumansMiceMice, Inbred C57BLMice, KnockoutMiddle AgedNeutrophilsSepsisSignal TransductionTriggering Receptor Expressed on Myeloid Cells-1TREM1 protein, mouseTriggering Receptor Expressed on Myeloid Cells-1endothelial cell activationLR12NETssepsisTREM-1vascular dysfunction

Identifiers

PMID33420354
PMCPMC8026640
OpenAlexW3118828853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.